Intraportal Infusion of Bone Marrow Mononuclear or Cd133+ Cells in Patients With Decompensated Cirrhosis: A Double-Blind Randomized Controlled Trial Publisher Pubmed



Mohamadnejad M^{1, 2} ; Vosough M³ ; Moossavi S^{1, 2} ; Nikfam S^{1, 2} ; Mardpour S³ ; Akhlaghpoor S⁴ ; Ashrafi M^{1, 2} ; Azimian V³ ; Jarughi N³ ; Hosseini SE³ ; Moeininia F⁵ ; Bagheri M^{1, 2} ; Sharafkhah M^{1, 2} ; Aghdami N³ Show All Authors
Source: Stem Cells Translational Medicine Published:2016

Abstract

The present study assessed the effects of intraportal infusions of autologous bone marrow-derived mononuclear cells (MNCs) and/or CD133+ cells on liver function in patients with decompensated cirrhosis. We randomly assigned 27 eligible patients to a placebo, MNCs, and/or CD133+ cells. Cell infusions were performed at baseline and month 3. We considered the absolute changes in the Model for End-Stage Liver Disease (MELD) scores at months 3 and 6 after infusion as the primary outcome. The participants and those who assessed the outcomes were unaware of the treatment intervention assignments. After 6 months, 9 patients were excluded because of liver transplantation (n = 3), hepatocellular carcinoma (n = 1), loss to follow-up (n = 3), and death (n = 2). The final analysis included 4 patients from the CD133+ group, 8 from the MNC group, and 6 from the placebo group. No improvement was seen in the MELD score at month 6 using either CD133+ cells or MNC infusions compared with placebo. However, at month 3 after infusion, a trend was seen toward a higher mean absolute change in the MELD score in patients who had received CD133+ cells compared with placebo (−2.00 ± 1.87 vs. −0.13 ± 1.46; p = .08). No significant adverse events occurred in the present study. A transient improvement in the MELD score was observed in subjects treated with CD133+ cells but not in the MNC or placebo group. Although the study was not powered to make definitive conclusions, the data justify further study of CD133+ therapy in cirrhotic patients. © AlphaMed Press.